Eton Pharmaceuticals, Inc. ETON
50.72 USD -0.23 (-0.45%)
At closeNov 4, 2026, 4:21 PM EST
50.72 0.00 0.00%
After hours · Nov 4, 4:21 PM ET
49.35 Day range 52.30
14.27 52-week range 66.37
- YTD
- +199.94%
- 1 year
- +174.91%
- Market cap
- 1.45B
- Revenue (ttm)
- 105.59M
- Profit margin
- 12.02%
- EPS (ttm)
- 0.40
- Shares out
- 28.58M
- P/E ratio
- 126.80
- Forward P/E
- 19.89
- YTD return
- +199.94%
- 1-year return
- +174.91%
- Volume
- 375.27K
- Avg volume
- 564.28K
- Open
- 51.76
- Previous close
- 50.95
- Day's range
- 49.35 – 52.30
- 52-week range
- 14.27 – 66.37
- Beta
- 0.83
- Price target
- 71.50 (+41.0%)
- Earnings date
- Nov 5, 2026
YTD +34.46 (+211.93%)
Key statistics
- Enterprise value
- 1.46B
- PEG ratio
- 0.00
- Price / sales
- 13.73
- Price / book
- 30.80
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 98.60%
- Free cash flow
- 6.58M
- Total cash
- 26.84M
- Total debt
- 29.23M
- Return on equity
- 35.97%
- Short % of float
- 9.40%
- 50-day average
- 55.48
- 200-day average
- 36.06
Analyst view
Price target (mean) 71.50 +41.0% upside
Now 50.72
- Target (low)
- 68.00
- Target (mean)
- 71.50
- Target (high)
- 78.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy0
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate 0.37.
Financials — quick view
ETON Revenue — quarterly 37.59M
ETON Net income — quarterly 11.58M
ETON EPS — quarterly 0.42
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | 0.3125 | — | — | — |
| Aug 13, 2026 | Jun 30, 2026 | 0.1898 | 0.35 | +0.16 | +84.40% |
| May 14, 2026 | Mar 31, 2026 | 0.10 | 0.05 | -0.05 | -50.00% |
| Mar 19, 2026 | Dec 31, 2025 | 0.12 | 0.05 | -0.07 | -58.33% |
| Nov 6, 2025 | Sep 30, 2025 | 0.16 | -0.07 | -0.23 | -143.75% |
| Aug 7, 2025 | Jun 30, 2025 | -0.01 | -0.10 | -0.09 | -900.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 14, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 14, 2026 | Canaccord Genuity | main | Buy | Buy |
| Aug 14, 2026 | B. Riley Securities | reit | Buy | Buy |
| Aug 14, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 11, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 28, 2026 | Craig-Hallum | main | Buy | Buy |
About Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- etonpharma.com
News
Eton Pharmaceuticals to Present at 2026 Jefferies Global Healthcare Conference in London 
Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update 
ETON Gears Up to Report Q3 Earnings: What Can Investors Expect? 
Eton Pharmaceutical Announces New Development Program ET-900 Evaluating Mecasermin Injection For Treatment Of Infantile And Epileptic Spasms; Plans To Dose First Patient In Q1 2027 
Eton Pharmaceuticals Announces Licensing and Initiation of ET-900 Program Evaluating Mecasermin/IGF-1 for Treatment of Infantile and Epileptic Spasms 
Eton Pharmaceuticals to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026 
Eton Pharmaceuticals, Inc. $ETON Shares Newly Bought by Robeco Institutional Asset Management B.V. 
Eton Pharmaceuticals Lands Exclusive US Rights To Aquestive's Seizure Rescue Drug 
HC Wainwright & Co. Reiterates Buy on Eton Pharmaceuticals, Maintains $70 Price Target 
Eton Pharmaceuticals And Aquestive Therapeutics Enter Exclusive U.S. License And Supply Agreement For LIBERVANT Buccal Film For Seizure Clusters In Patients With Epilepsy; Sees Commercial Availability In April 2027
Your note
Sign in to keep a note on ETON — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ADAMS JENNIFER MCKIE | Director | Sale | Jun 16, 2026 | 0 |
| BRYNJELSEN SEAN E | Chief Executive Officer | Sale | Aug 19, 2026 | 961,194 |
| GRUBER JAMES R | Chief Financial Officer | Sale | Aug 19, 2025 | 204,753 |
| KREMPA DAVID | Officer | Sale | Oct 5, 2026 | 43,381 |
| MAIER PAUL V | Director | Sale | Aug 27, 2026 | 59,745 |
| OPALEYE MANAGEMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | Sale | Jul 13, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Opaleye Management Inc. | 10.01% | 2,860,000 | 145.06M | Jun 29, 2026 |
| EcoR1 Capital, LLC | 7.60% | 2,171,938 | 110.16M | Jun 29, 2026 |
| Blackrock Inc. | 6.63% | 1,895,833 | 96.16M | Jun 29, 2026 |
| Nantahala Capital Management, LLC | 4.11% | 1,175,951 | 59.64M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 3.42% | 976,570 | 49.53M | Jun 29, 2026 |
| Morgan Stanley | 2.69% | 767,972 | 38.95M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Russell 2000 ETF | 2.42% | 690,942 | 35.04M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.40% | 684,821 | 34.73M | Jun 29, 2026 |
| OBERWEIS FUNDS-Oberweis Micro-Cap Fund | 1.69% | 483,900 | 24.54M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.02% | 292,342 | 14.83M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.95% | 271,079 | 13.75M | Jun 29, 2026 |
| TIAA-CREF Funds-Nuveen Quant Small Cap Equity Fund | 0.89% | 253,380 | 12.85M | Jul 30, 2026 |